The largest database of trusted experimental protocols

Human collagen type 3

Manufactured by Southern Biotech
Sourced in United States, Germany

Human collagen type III is a purified form of collagen, a structural protein found naturally in the human body. It is primarily responsible for providing strength and support to various tissues, including skin, organs, and blood vessels. This product is suitable for use in research applications that require a reliable source of human collagen type III.

Automatically generated - may contain errors

5 protocols using human collagen type 3

1

Cone and Plate(let) Analysis of Inositol Phosphates

Check if the same lab product or an alternative is used in the 5 most similar protocols
To perform cone and plate(let) analysis (CPA) we employed the Impact-R device [18] (link), [19] (link) (DiaMed, Switzerland). Citrated whole blood was collected from at least three volunteers and allowed to rest for 45 min at RT. Then, 16 µM InsPs (InsP3, InsP5 or InsP6) or the corresponding volume of PBS in absence or presence of 2.8 µg/ml abciximab (ReoPro®, Lilly Deutschland GmbH, Bad Homburg, Germany) were added and mixed for 1 min at 10 rpm on the tube rotator of the Impact-R device.
When using washed blood, fibrinogen (1.5 mg/ml) was added to facilitate aggregate adhesion. CPA samples contained 16 µM InsPs (InsP3, InsP5 or InsP6) with or without either additional 1.5 mg/ml fibrinogen, 10 µg/ml rVWF (produced as previously described [20] (link)), or 3 µg/ml human collagen type III (Southern Biotech, Biozol, Eching, Germany). After an incubation of 5 min, the samples were mixed at 10 rpm for 1 min.
For CPA, 130 µl of each sample were subjected to flow for 2 min at a defined shear rate of 720 rpm (corresponding to 1800 s−1). Subsequently, the wells were washed with PBS, stained with May-Grünwald solution (Roth, Karlsruhe, Germany) for 1 min and further analyzed with the internal image analyzer of the Impact-R device. Platelet aggregation was evaluated by examining the average size (AS) of surface-bound objects [21] .
+ Open protocol
+ Expand
2

Synthesis and Characterization of Inositol Phosphates

Check if the same lab product or an alternative is used in the 5 most similar protocols
InsP5 (triethylammonium salt) was synthesised as previously reported [12] (link). InsP3 (potassium salt) was purchased from Buchem B.V. (Apeldoorn, The Netherlands), InsP6 (potassium salt) from Millipore (Darmstadt, Germany), apyrase from potato and human fibrinogen (purified from plasma) were purchased from Sigma Aldrich (Munich, Germany), fibrinogen from human plasma Alexa Fluor 488 conjugate from Thermo Fisher Scientific (Darmstadt, Germany), human α-thrombin from Haematologic Technologies Inc (Essex Junction, VT, USA), t-PA from Haemachrom (Essen, Germany), Glu-Plasminogen from Enzyme Research Laboratories (South Bend, IN, USA), human collagen type III from Southern Biotech (Birmingham, AL, USA) and May-Grünwald solution from Carl Roth (Karlsruhe, Germany). Chemicals for all buffers described below were purchased from Sigma Aldrich (Munich, Germany).
+ Open protocol
+ Expand
3

VWF-Fibronectin Interaction Inhibition Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies were tested for their ability to inhibit VWF‐fibronectin interactions. Inhibitory testing was done by ELISA, as described above, with variation in the VWF treatment step. The antibodies were diluted to 50 μg/mL in blocking buffer and added to the VWF solution. The fibronectin‐coated plates were then treated with the VWF‐antibody mixture at room temperature for 1 hour. Antibody testing included monoclonal anti‐VWF antibodies (AVW‐3 and AVW‐5, mouse anti‐human VWF, Versiti Blood Research Institute), monoclonal anti‐fibronectin (mouse anti‐human fibronectin, Thermo Fisher Scientific), and a polyclonal anti‐VWF antibody (rabbit anti‐human VWF; Dako, Glostrup, Denmark). ECM proteins were tested to examine if they could inhibit binding of fibronectin to VWF. Human fibronectin, laminin (EMD Millipore, Billerica, MA, USA), thrombospondin (Haematologic Technologies, Inc.), and vitronectin (Haematologic Technologies, Inc.) were individually diluted to 10 μg/mL and incubated with VWF before plating. Inhibitory testing was also performed with human collagen type III (Southern Biotech, Birmingham, AL, USA) and human collagen type IV (Southern Biotech) at 25 μg/mL.
+ Open protocol
+ Expand
4

Cone and Plate(let) Analysis of Inositol Phosphates

Check if the same lab product or an alternative is used in the 5 most similar protocols
To perform cone and plate(let) analysis (CPA) we employed the Impact-R device [18 (link), 19 (link)] (DiaMed, Switzerland). Citrated whole blood was collected from at least three volunteers and allowed to rest for 45 min at RT. Then, 16 μM InsPs (InsP3, InsP5 or InsP6) or the corresponding volume of PBS in absence or presence of 2.8 μg/ml abciximab (ReoPro®, Lilly Deutschland GmbH, Bad Homburg, Germany) were added and mixed for 1 min at 10 rpm on the tube rotator of the Impact-R device.
When using washed blood, fibrinogen (1.5 mg/ml) was added to facilitate aggregate adhesion. CPA samples contained 16 μM InsPs (InsP3, InsP5 or InsP6) with or without either additional 1.5 mg/ml fibrinogen, 10 μg/ml rVWF (produced as previously described [20 (link)]), or 3 μg/ml human collagen type III (Southern Biotech, Biozol, Eching, Germany). After an incubation of 5 min, the samples were mixed at 10 rpm for 1 min.
For CPA, 130 μl of each sample were subjected to flow for 2 min at a defined shear rate of 720 rpm (corresponding to 1800 s-1). Subsequently, the wells were washed with PBS, stained with May-Grünwald solution (Roth, Karlsruhe, Germany) for 1 min and further analyzed with the internal image analyzer of the Impact-R device. Platelet aggregation was evaluated by examining the average size (AS) of surface-bound objects [21 ].
+ Open protocol
+ Expand
5

Synthesis and Characterization of Inositol Phosphates

Check if the same lab product or an alternative is used in the 5 most similar protocols
InsP5 (triethylammonium salt) was synthesised as previously reported [12 (link)]. InsP3 (potassium salt) was purchased from Buchem B.V. (Apeldoorn, The Netherlands), InsP6 (potassium salt) from Millipore (Darmstadt, Germany), apyrase from potato and human fibrinogen (purified from plasma) were purchased from Sigma Aldrich (Munich, Germany), fibrinogen from human plasma Alexa Fluor 488 conjugate from Thermo Fisher Scientific (Darmstadt, Germany), human α-thrombin from Haematologic Technologies Inc (Essex Junction, VT, USA), t-PA from Haemachrom (Essen, Germany), Glu-Plasminogen from Enzyme Research Laboratories (South Bend, IN, USA), human collagen type III from Southern Biotech (Birmingham, AL, USA) and May-Grünwald solution from Carl Roth (Karlsruhe, Germany). Chemicals for all buffers described below were purchased from Sigma Aldrich (Munich, Germany).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!